Klaria Pharma Holding AB — Investor Relations & Filings

Klaria Pharma Holding AB is a pharmaceutical company that develops innovative, rapid-acting medicinal products. The company's core technology is a proprietary transmucosal drug delivery platform. This platform uses an alginate-based polymer film that adheres to the oral mucosa, enabling fast and direct absorption of active pharmaceutical ingredients into the bloodstream. This delivery method offers advantages for conditions requiring a quick onset of effect, bypassing the gastrointestinal tract. The company's development pipeline focuses on therapeutic areas such as migraine, cancer-related pain, and opioid overdose. A key product in its portfolio is a formulation of Sumatriptan for the acute treatment of migraine.